Depression and schizophrenia are two highly prevalent and severely debilitating neuropsychiatric disorders. Both conventional antidepressant and antipsychotic pharmacotherapies are often inefficient clinically, causing multiple side effects and serious patient compliance problems. Collectively, this calls for the development of novel drug targets for treating depressed and schizophrenic patients. Here, we discuss recent translational advances, research tools and approaches, aiming to facilitate innovative drug discovery in this field. Providing a comprehensive overview of current antidepressants and antipsychotic drugs, we also outline potential novel molecular targets for treating depression and schizophrenia. We also critically evaluate multiple translational challenges and summarize various open questions, in order to foster further integrative cross-discipline research into antidepressant and antipsychotic drug development.
In recent decades, obesity has become a pandemic disease and appears to be an ultimate medical and social problem. Existing antiobesity drugs show low efficiency and a wide variety of side effects....
1 July 2023 in Neuroscience and Behavioral Physiology
Peripheral tissue damage or nerve injury often leads to development of pathological pain processes, such as spontaneous pain, hyperalgesia and allodynia that persist for years or decades after all possible tissue healing has occurred. The modification of classic formalin test with two subsequent injections of formalin can be useful to investigate central mechanisms of “pain memory”. To evaluate the effect of analgesia of periphery on central pathways of nociception we used four groups of analgesics: a local anaesthetic-lidocaine, NSAID-diclofenac, a mu-opioid receptor agonist-DAMGO, anticonvulsant with chronic pain-relieving action-gabapentin. We studied the impact of analgesic drugs on acute and chronic pain conditions taking as a basis c-Fos as a pain intensity marker.
Pain is one of the most frequent symptoms accompanying diseases. Every type of pain invokes various molecular mechanisms leading to the central effects, and hence the pain response. The plasticity of the nervous system is a unique property enabling it to change the number and quality of neural connections in order to adapt to the environment. This property is the basis of memory, particularly “pain memory”. The formalin test is widely used as an experimental model of biphasic pain in laboratory animals. We supposed that adding the second injection of a noxious agent to the classical test will enhance the pain response and let us observe plastic changes in the central nervous system and in the periphery. The contralateral repetitive injection of formalin and capsaicin to the rat hind paw revealed an increase in pain score in Phase 1 and a decrease in Phase 2. In Freund’s adjuvant injected group the pain score in both phases was increased. Different patterns of spinal cord neuronal activity were observed in formalin, capsaicin, and Freund’s adjuvant injections. Contralateral repetitive administration of formalin and capsaicin, but not Freund’s adjuvant revealed a “pain memory”, a pain response in previously injected but unaffected in the second injection paw. Analysis of the “pain memory” based on our previous studies revealed its overall central character and lack of association with inflammation. Investigations of mechanisms underlying each type of pain and deep analysis of pain memory may open new perspectives to prevent and treat pain.